What challenges did AstraZeneca face before AI implementation?

Fragmented, siloed data ecosystems across pharma R&D, clinical, regulatory, and supply chain environments. Legacy IT infrastructure not optimized for modern AI workloads, causing integration bottlenecks. Escalating R&D costs, lengthy drug development timelines (often 15 years or more), and high clinical trial expenses. Regulatory uncertainty and evolving compliance requirements impede rapid AI deployment. Low user adoption/ROI on pilot AI deployments due to organizational silos and insufficient frontline engagement.

Source

Microsoft ExpandedPilotEvidence: Medium50/100

AstraZeneca and Novartis Scale AI Across Pharma Value Chain

Use case typePatient engagementUpdated Jun 13, 2026

This article provides a comprehensive overview of how leading pharmaceutical firms—including AstraZeneca, Novartis, Sanofi, GSK, Genentech, and AbbVie—are integrating Microsoft technologies such as Azure AI, Machine Learning, Cognitive Services, and Power Platform to transform drug development and operations. Real-world examples cover AI-powered drug target identification, generative molecule design, clinical trial acceleration, pharmacovigilance, supply chain optimization, and patient engagement via chatbots. The piece details both the tangible business benefits (shortened timelines, reduced costs, improved trial precision, and better patient outcomes) and persistent challenges such as data fragmentation, legacy systems, regulatory complexities, and change management. Strategic priorities for CIOs and IT leaders on how to industrialize AI, ensure enterprise-wide adoption, and promote responsible, cross-functional scaling of Microsoft technologies are emphasized. The article highlights collaborations like AstraZeneca’s enterprise AI roadmap, Novartis-Microsoft innovation lab, and Sanofi’s infrastructure modernization to demonstrate mature, scalable uses of cloud-based AI. Challenges with data interoperability, legacy infrastructure, talent and cultural adoption, and regulatory risk are addressed alongside solutions such as human-in-the-loop designs, explainable AI, and real-time learning cycles aligned with scientific and compliance goals.

Organization: AstraZeneca
Industry: Pharma
Location: Global
Published: April 2025

Reported outcomes

Time: Up to 70% lower

Time & speed

Time: Up to 80% lower

Planned next steps

The source says the organization aims to achieve: Accelerated drug discovery and design.

Why do we believe this?Outcome claims, sources, and evidence checks

Normalized claim

Time: 70% decrease

WhatfixApr 30, 2025Blog postInferred claimMedium evidence strength

Reduced clinical trial costs by up to 70% and timelines by up to 80% in some deployments.

Normalized claim

Time: 80% decrease

WhatfixApr 30, 2025Blog postInferred claimMedium evidence strength

Reduced clinical trial costs by up to 70% and timelines by up to 80% in some deployments.

Why do we believe this deployment?Customer identity, provider attribution, maturity, and source checks

Customer: AstraZeneca, Novartis, Sanofi, GSK, Genentech, AbbVie
Provider: Microsoft, AWS
Maturity: Pilot
Linked source: Whatfix

Low user adoption/ROI on pilot AI deployments due to organizational silos and insufficient frontline engagement

Customer identity supportedSource describes one deploymentMaturity supported

Primary read

Use case focus

Showing 3 of 6

1AI-powered Drug Target Identification
2Generative Design of Drug Molecules
3Predictive Analytics for Clinical Trial Outcomes

Fragmented, siloed data ecosystems across pharma R&D, clinical, regulatory, and supply chain environments.
Legacy IT infrastructure not optimized for modern AI workloads, causing integration bottlenecks.
Escalating R&D costs, lengthy drug development timelines (often 15 years or more), and high clinical trial expenses.
Regulatory uncertainty and evolving compliance requirements impede rapid AI deployment.
Low user adoption/ROI on pilot AI deployments due to organizational silos and insufficient frontline engagement.

Deployment of Microsoft Azure AI, Machine Learning, Cognitive Services, and Power Platform to enable scalable AI workflows.
Enterprise-wide adoption of responsible AI/ML—powered platforms for drug design, clinical trial support, and pharmacovigilance.
Strategic modernization of infrastructure, including cloud-based platforms with robust MLOps pipelines (e.g., Sanofi).
Co-innovation programs such as Novartis-Microsoft AI labs for cross-functional collaboration and human-in-the-loop design.
Use of Power Platform for rapid prototyping, compliance monitoring, and IT enablement across business units.

Technologies

Azure AI Machine Learning Cognitive Services Power Platform

Enhancements in compliance monitoring, supply chain accuracy, and engagement through AI-powered support systems.

Architecture

Multiple pharmaceutical organizations have integrated Microsoft Azure AI, Cognitive Services, and Power Platform into cloud-scale enterprise architectures: (1) Data lakes unify cross-domain R&D and clinical trial data; (2) MLOps pipelines automate and monitor model lifecycle, including regulatory-compliant workflow management; (3) Cross-functional collaboration is enabled through joint innovation labs and shared data access; (4) Human-in-the-loop design combines automated AI recommendations with clinical expert oversight.

Sources & evidence1

Evidence: Medium50/100Evidence strength